Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Information source: Talecris Biotherapeutics
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Purpura, Thrombocytopenic, Idiopathic
Intervention: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified (Drug)
Phase: Phase 2
Sponsored by: Talecris Biotherapeutics
Official(s) and/or principal investigator(s):
James Bussel, MD, Principal Investigator, Affiliation: New York Presbyterian Hospital-Weill Medical College of Cornell University
The objective of this study is to determine if the safety and tolerability of Immune Globulin
Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at
two different infusion rates.
Official title: Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP)
Study design: Treatment, Randomized, Open Label, Dose Comparison, Crossover Assignment, Safety Study
Primary outcome: Hemolysis
All adverse events
Infusion related adverse events
This is a prospective, randomized, single-center, open, cross-over trial in patients with a
confirmed diagnosis of Idiopathic Thrombocytopenia Purpura (ITP). ITP is defined as isolated
thrombocytopenia in a patient with no other clinically apparent associated conditions or
factors that are known to cause thrombocytopenia as defined by the ITP Practice Guidelines
Committee of the American Society of Hematology.
Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) at a dose
of 1. 0 g/kg will be given on 2 occasions as a single daily infusion for platelet counts <
30,000 uL or if clinically indicated, at maximum intervals of six weeks. Eligible patients
will be randomized into one of two cross-over groups. Patients randomized to Group 1 will
receive their first IGIV-C infusion at a rate of 0. 08 mL/kg/min and their second infusion
at a rate of 0. 14 mL/kg/min. Conversely patients randomized to Group 2 will receive their
first IGIV-C infusion at a rate of 0. 14 mL/kg/min and their second infusion at a rate of
0. 08 mL/kg/min according to the following schema:
- Infusion #1 (Week 0) IGIV-C (0. 08 mL/kg/min)
- Infusion #2 (Week <6) IGIV-C (0. 14 mL/kg/min)
- Infusion #1 (Week 0) IGIV-C (0. 14 mL/kg/min)
- Infusion #2 (Week <6) IGIV-C (0. 08 mL/kg/min)
Minimum age: 12 Years.
Maximum age: 75 Years.
- Written informed consent from patient or legal guardian (according to institutional
review board requirements)obtained prior to initiation of any study related
- Male and female subjects age between 12 and 75 years
- Confirmed diagnosis of ITP logged in medical records available prior to entry into the
- Patients must have a platelet count < 30 x 10E9/L (this level can be higher if
- Previously splenectomized patients may be included.
- Any previously conducted bone marrow aspirations if conducted following diagnosis of
ITP must be consistent with the ITP diagnosis (increased or normal levels of
megakaryocytes in otherwise normal bone marrow).
- History of allergic or other clinically significant reaction to human gamma globulin
or other plasma proteins and/or blood products.
- Female patient who is pregnant or lactating or is not on an adequate program of
contraception if of child-bearing potential.
- Documented history of selective IgA deficiency (serum <5. 0 mg/dL) and known antibodies
- Currently on intermittent prednisone therapy. Prednisone therapy is allowed only if
the patient has been on stable daily doses of prednisone for the preceding month and
maintains the same treatment regimen throughout the study.
- Renal or liver impairment defined by creatinine > 2. 5 mg/dL, or direct bilirubin >1. 5
X the upper limit of normal or liver transaminases (AST or ALT) > 3 times the upper
limit of normal.
- Received anti-D or IGIV infusions within the past 14 days
- Pre-treatment with the exception of acetominophen, routinely required to
control/ameliorate IGIV infusion-related adverse events (AEs), or any patient who has
been, unresponsive to IGIV therapy for their ITP
- History or clinical evidence of medical conditions felt to be the underlying cause of
their thrombocytopenia. Such conditions commonly include systemic lupus
erythematosus, history of chronic lymphocytic leukemia, dysplasia, agammaglobulinemia,
treatment with heparin, quinidine, quinine, trimethoprim-sulfamethoxazole, or
ticlopidine or any other drug thought to be the cause of patient's thrombocytopenia,
congenital or hereditary thrombocytopenia, or pseudothrombocytopenia (clumping on
peripheral blood smear)
- Conditions that could alter protein catabolism and/or IgG utilization (e. g.
protein-losing enteropathies, nephrotic syndrome)
- Congestive heart failure (New York Heart Association Stage III or IV)
- Diabetes mellitus
- Concomitant nephrotoxic drugs
- Hemoglobin level more than 2g/L below the lower limit of normal.
Locations and Contacts
New York Presbyterian Hospital, New York, New York 10021-4885, United States
Study Synopsis of Results
FDA-Approved Product Labeling - Gamunex®
FDA Product Approval - Gamunex®
Bussel JB, Hanna K; IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Am J Hematol. 2007 Mar;82(3):192-8.
Starting date: July 2003
Ending date: October 2003
Last updated: March 31, 2008